Stock listing

BIIBD Stock Price, News, Filings & Events — Biogen Inc.

Selected listing: BIIBD · BCBA · USD · AR

This page tracks Biogen Inc.'s BIIBD:BCBA listing on BCBA in USD for AR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BIIBD:BCBA. BIIBD:BCBA is the stock-level entry point for investors researching Biogen Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Biogen Inc. is a publicly traded biotechnology company based in America, with a market capitalization of approximately $29.4 billion. The company focuses on developing therapies for neurological diseases and has a strong portfolio of innovative treatments. Biogen is committed to advancing scientific research and improving patient outcomes in the field of neuroscience.

BIIBD:BCBAUSDARUpdated July 31, 2026
Biogen Inc. logo
Ticker
BIIBD:BCBA
Asset type
Stock
Market cap
$29.99B
Sector
Health Technology
Industry
Pharmaceuticals: Major
Exchange
BCBA
Currency
USD

Biogen Inc. BIIBD:BCBA stock context

This page tracks Biogen Inc.'s BIIBD:BCBA listing on BCBA in USD for AR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BIIBD:BCBA. BIIBD:BCBA is the stock-level entry point for investors researching Biogen Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Biogen Inc. is a publicly traded biotechnology company based in America, with a market capitalization of approximately $29.4 billion. The company focuses on developing therapies for neurological diseases and has a strong portfolio of innovative treatments. Biogen is committed to advancing scientific research and improving patient outcomes in the field of neuroscience.

Latest news from Biogen Inc.

All Biogen Inc. news →

Research Biogen Inc.

Alternate listings